Tag: Tonix Pharmaceuticals

November 21, 2019

Tonix Pharmaceuticals Begins Phase 3 RELIEF Study

The company announced that its Phase 3 RELIEF Study will evaluate its TNX-102- SL in patients with fibromyalgia.
August 20, 2019

Tonix Pharmaceuticals Expands Preclinical Pipeline

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) has announced an exclusive agreement to in-license a triple reuptake inhibitor, TNX-1600, to treat post-traumatic stress...
May 23, 2019

Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate

Tonix Pharmaceuticals (NASDAQ:TNXP) has announced that it has in-licensed a Phase 2 asset, TNX-1300 for treating cocaine intoxication. As quoted...
January 1, 2019

An Investor’s Guide to Clinical Trials

Clinical trials can be one of the more challenging US Food and Drug Administration processes to understand, but grasping the...
March 22, 2018

Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL

Tonix Pharmaceuticals (Nasdaq:TNXP) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products...
January 23, 2018

Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent

Tonix Pharmaceuticals Holding (Nasdaq:TNXP) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S....
January 22, 2018

Tonix Pharmaceuticals Announces Publication Reporting a Potential Smallpox-Preventing Vaccine Candidate

Tonix Pharmaceuticals (Nasdaq:TNXP) a company developing innovative pharmaceutical and biological products to address major public health challenges, announced the publication...